Engage Therapeutics innovative inhalation therapy reaches the clinical end of Phase 2b.

Seizures can lead to uncontrollable physical movement, abnormal thinking and behavior, and abnormal perception.
physical movement can be very intense and lead to loss of consciousness.
epilepsy is produced because a group of nerve cells in the brain are uncontrolledly activated, and episode epilepsy refers to the fact that seizures originate in a limited part of the brain.
there are already two approved nasal spray treatments on the market, but they take at least 15 minutes to take effect, meaning they are too late to end seizures that have already begun.
Staccato alprazolam is a small hand-held oral inhalation epileptic emergency treatment that combines the FDA-approved Staccato delivery technology with the listed drug alprazolam.
can easily deliver apopium with just one inhalation.
Staccato system sepulchratosis can be rapidly evaporated, forming an aerosol, particles that can be used for deep lung transport to produce rapid systemic effects.
this may provide an effective way for people with epilepsy and their caregivers to prevent active seizures.
Staccato alprazolam (Photo Source: Engage Therapeutics) StATES Trial is a randomized, double-blind phase 2b clinical study involving 116 patients to assess the safety, effectiveness and availability of Staccato alprazolam in the treatment of adults with terretomy or systemic seizures.
the results of the trial, 50 out of 76 patients reached the primary endpoint, meaning that the patient stopped with epilepsy within two minutes of treatment and did not relapse within two hours. "I believe that the treatment of epilepsy needs to take effect quickly and stop the disease in time for a seizure," said Gregory T. Mayes, founder and CEO of States Research, "the data from the States study confirm the rapid entry of Staccato alprazolam," said Gregory T. Mayes, founder and CEO of States.

as clinical trials progress, we hope to see As soon as possible that Staccato alprazolam is an important tool for people with epilepsy to alleviate the disease.
" References: 1. Engage Therapeutics Announces Phase 2b StATES Study of Staccato ® Alprazolam for The Samet Sbyer Primary Endpoint, Retrieved March 12, 2020, from the "from" Engage Touts Long-Ed Positive data for the inhaler for the Retrieved March 12, 2020, from the original title: Express. End seizures within 30 seconds, and innovative inhalation therapy reaches stage 2b clinical endpoint.